魏金蓮 副教授/碩士生導(dǎo)師
地址：上海市徐匯區(qū)梅隴路130號(hào)實(shí)驗(yàn)十八樓431室
上海市奉賢區(qū)海思路999號(hào)華東理工大學(xué)實(shí)驗(yàn)五樓309室
Email：weijinlian678@ecust.edu.cn
郵編：200237
個(gè)人簡(jiǎn)介
研究方向主要致力于抗腫瘤候選新藥的研發(fā)，基于團(tuán)隊(duì)老藥新用與老藥二次研發(fā)創(chuàng)新策略，建立了完備的從“體外抗腫瘤表型篩選→機(jī)制確證與化學(xué)生物學(xué)研究→結(jié)構(gòu)修飾與構(gòu)效關(guān)系研究→動(dòng)物藥效與成藥性評(píng)價(jià)”的技術(shù)平臺(tái)體系。近年來(lái)，以第一/通訊作者在Acta Pharm. Sin. B、Cell Death Dis.、J. Med. Chem.等國(guó)內(nèi)外知名學(xué)術(shù)期刊發(fā)表多篇SCI文章，并申請(qǐng)發(fā)明專利。入選上海市“超級(jí)博士后”激勵(lì)計(jì)劃，先后主持國(guó)家自然科學(xué)基金青年基金項(xiàng)目、面上項(xiàng)目。
教育經(jīng)歷
2012.09–2017.06，中國(guó)藥科大學(xué)，藥學(xué)院，制藥工程學(xué)，碩博，導(dǎo)師：尤啟冬教授；
2008.09–2012.06，中國(guó)藥科大學(xué)，藥學(xué)院，制藥工程，學(xué)士。
工作經(jīng)歷
2024.01-至今，華東理工大學(xué)，藥學(xué)院，副教授；
2022.08–2023.12，華東理工大學(xué)，藥學(xué)院，講師；
2020.01–2022.07，華東理工大學(xué)，藥學(xué)院，博士后，合作導(dǎo)師：李劍教授；
2017.07–2019.12，華東理工大學(xué)，藥學(xué)院，思政。
主要研究方向
1. 老藥新用與老藥二次研發(fā)
2. 抗腫瘤創(chuàng)新藥物的研發(fā)與新靶標(biāo)機(jī)制研究
榮譽(yù)及社會(huì)兼職
1. 2024年，中國(guó)國(guó)際大學(xué)生創(chuàng)新大賽(2024)，上海賽區(qū)銀獎(jiǎng)，指導(dǎo)教師。
2. 2023年，華東理工大學(xué)青年五四獎(jiǎng)?wù)拢▊€(gè)人）。
3. 2022年，第八屆中國(guó)國(guó)際“互聯(lián)網(wǎng)﹢”大學(xué)生創(chuàng)新創(chuàng)業(yè)大賽，國(guó)家級(jí)銅獎(jiǎng)，指導(dǎo)教師。
4. 2022年，第十三屆“挑戰(zhàn)杯”全國(guó)大學(xué)生創(chuàng)業(yè)計(jì)劃競(jìng)賽，上海賽區(qū)銀獎(jiǎng)，指導(dǎo)教師。
5. 2021年，第七屆中國(guó)國(guó)際“互聯(lián)網(wǎng)﹢”大學(xué)生創(chuàng)新創(chuàng)業(yè)大賽，上海賽區(qū)銀獎(jiǎng)，指導(dǎo)教師。
6. 《中國(guó)藥科大學(xué)學(xué)報(bào)》青年編委。
7. 中國(guó)醫(yī)藥信息學(xué)會(huì)中醫(yī)臨床藥學(xué)分會(huì)理事。
歡迎有志于藥物化學(xué)、藥理學(xué)以及新藥研發(fā)領(lǐng)域研究的學(xué)生加入！
招生專業(yè)：學(xué)術(shù)碩士(藥學(xué)100700）；專業(yè)碩士（藥學(xué)105500）
代表性論文(#共同第一作者，*為通訊作者)
1. Liang Liao#, Qiang Wang#, Zhengyang Gao#, Jiayao Liu, Yuxuan Tong, Xin Chen, Jin Zhu, Jian Li*, Jinlian Wei*. Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies. Acta Pharm. Sin. B. 2025, https://doi.org/10.1016/j.apsb.2025.10.033.
2. Guangwei Cui#, Yuhang Fan#, Yue Yang, Yiwen Ma, Haiyang Deng, Pan Wang, Yuxin Zhu, Jian Li, Jinlian Wei*, Yongqiang Zhang*. Discovery of N-Trifluoromethylated Noscapines as Novel and Potent Agents for the Treatment of Glioblastoma. J. Med. Chem. 2025, 68, 247?260.
3. Shiqi Hu#, Yuhang Fan#, Yumo Zhao, Zhengyang Gao, Jie Lu, Jian Li, Jinlian Wei*, Yongqiang Zhang*. Design, synthesis and anti-GBM activities of amide-modified Curcumol derivatives. Bioorg. Med. Chem. Lett. 2025, 130265, 125–126.
4. Yumo Zhao; Yi Wan, Qiyang Yuan, Jinlian Wei*, Yongqiang Zhang*. Photocatalytic C?Si Bond Formations Using Pentacoordinate Silylsilicates as Silyl Radical Precursors: Synthetic Tricks Using Old Reagents, Org. Lett. 2023, 25: 1386-1391.
5. Jiajie Zhu , Yi Wan , Qiyang Yuan , Jinlian Wei *, Yongqiang Zhang *. Research of Visible Light/Lewis Base Dual Catalytic Defluorinative Silylation of Trifluoromethyl-Substituted Alkenes. Chin. J. Org. Chem. 2023, 43, 3623-3634.
6. JinlianWei#, Yongyun Li#, Ruoxi Li, Xin Chen, Tiannuo Yang, Liang Liao, Yuqing Xie, Jin Zhu, Fei Mao, Renbing Jia*, Xiaofang Xu*, Jian Li*. Drug Repurposing of Propafenone to Discover Novel Anti-tumor Agents by Impairing Homologous Recombination to Delay DNA Damage Recovery of Rare Disease Conjunctival Melanoma. Eur. J. Med. Chem. 2023, 250, 115238.
7. Jinlian Wei#, Xin Chen#, Yongyun Li#, Ruoxi Li, Keting Bao, Liang Liao, Yuqing Xie, Tiannuo Yang, Jin Zhu, Fei Mao, Shuaishuai Ni, Renbing Jia*, Xiaofang Xu*, Jian Li*. Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway. Acta Pharm. Sin. B. 2022, 12(10):3861-3876.
8. Keting Bao#, Yongyun Li#, Jinlian Wei#, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao*, Renbing Jia*, Jian Li*. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death Dis. 2021, 12 (4), 380.
9. Xin Chen#, Xi Yang#, Fei Mao#, Jinlian Wei#, Yixiang Xu, Baoli Li, Jin Zhu, Shuaishuai Ni*, Lijun Jia*, Jian Li*. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and in vivo. Eur. J. Med. Chem. 2021, 210, 112964.
10. Jinlian Wei, Yingrui Yang, Mengchen Lu, Yonghua Lei, Lili Xu, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Haopeng Sun*, Qidong You, Recent Advances in the Discovery of HIF-1alpha-p300/CBP Inhibitors as Anti-Cancer Agents. Mini-Rev. Med. Chem. 2018, 18 (4), 296-309.
11. Jinlian Wei, Yingrui Yang, Yali Li, Xiaofei Mo, Xiaoke Guo, Xiaojin Zhang, Xiaoli Xu, Zhengyu Jiang, Qidong You*, Synthesis and evaluation of N-(benzofuran-5-yl)aromaticsulfonamide derivatives as novel HIF-1 inhibitors that possess anti-angiogenic potential, Bioorg.Med. Chem. 2017, 25 (6): 1737-1746.
12. Xiaoli Xu, Yingrui Yang, Xiaofei Mo, Jinlian Wei, Xiaojin Zhang, Qidong You*, Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via in terfering the hypoxia environment by targeting HIF-1alpha pathway, Eur. J. Med. Chem. 2017, 137: 45-62.
13. Jinlian Wei, Yingrui Yang, Mengchen Lu, Lili Xu, Fang Liu, Zhenwei Yuan, Qichao Bao, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Qidong You*, Haopeng Sun*, Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination. Anticancer Agents Med. Chem. 2015, 16 (2): 174-189.
14. Yingrui Yang, Jinlian Wei, Xiaofei Mo, Zhenwei Yuan, Jialing Wang, Chao Zhang, Yieyue Xie, Qidong You*, Haopeng Sun*, Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway. Bioorg Med Chem Lett. 2016, 26 (11): 2713-2718.
15. Xin Xue, Jinlian Wei, Lili Xu, Meiyang Xi, Xiaoli Xu, Fang Liu, Xiaoke Guo, Lei Wang, Xiaojin Zhang, Mingye Zhang, Mengchen Lu, Haopeng Sun*, Qidong You*, Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors. J Chem Inf Model. 2013, 53 (10): 2715-2729.
